Search | Médecins Sans Frontières Access Campaign

2831 results found
There are 0 active filters

2831 results found

Yeshiwas Tesema MSF’s community and health education supervisor speaks about the risks of snakebites to migrant workers in Abdurafi town.

Research article |

21 December 2022

Toxicon: X: Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues

MSF authors describe medical activities for people for snakebite, including the importance of offering antivenom free of charge, though costly for MSF.

Tags Tropical & neglected diseases snakebite

MSF nurse Oleksandr Oleksandr Vovkogon observes Vitalii Gorbachov, 56, take his DR-TB pills at this home in Chudniv village, Zhytomyr region, Ukraine. In order to enhance patient autonomy, MSF’s programme offers a combination of directly-observed (DOT), video-observed (VOT) and self-administered (SAT) therapies, depending on the needs and capacity of the patients.

Press release |

15 December 2022

MSF responds to groundbreaking updated WHO guidelines for drug-resistant tuberculosis

The World Health Organization’s Global Tuberculosis Report 2022 highlights that still only one in three people with drug-resistant tuberculosis is getting treatment, and the treatment success rate for those who do receive treatment ...

Tags Tuberculosis GeneXpertpretomanidlinezolidbedaquiline TB AllianceCepheid

Letter |

06 December 2022

The Lancet Gastroenterology & Hepatology: An open letter to Gavi: hepatitis B birth dose vaccine can't wait

MSF and others call on Gavi to immediately start its hepatitis B birth dose vaccination programme

Tags Vaccines hepatitis B Gavi, the Vaccine Alliance

Letter |

05 December 2022

Civil Society Open Letter to the Council of the European Union Concerning Transferable Exclusivity Vouchers for Antimicrobials

MSF and CSOs urge the European Council to reject the introduction of transferable exclusivity vouchers (TEVs) for the development of antimicrobial drugs

Tags Intellectual property and trade antimicrobial resistance TRIPS WTO

Video |

01 December 2022

Working for access to long-acting cabotegravir for HIV prevention

This video highlights the benefits of long-acting cabotegravir (CAB-LA) to prevent HIV in vulnerable populations and the work of the Access Campaign to overcome access barriers to CAB-LA.

Aisha Diabate 30 years (background) arrived at MSF’s specialised AIDS unit in Donka University Hospital with the husband of her sister who is a doctor from Coleah health centre in Conakry.

Press release |

29 November 2022

Pharmaceutical corporation ViiV must make ground-breaking HIV prevention injection affordable and available

MSF calls on ViiV to urgently dismantle barriers to access for long-acting cabotegravir

Tags HIV/AIDS HIV/AIDS cabotegravir World Health OrganizationViiV

Blog |

17 November 2022

How much do clinical trials cost? The answer is overdue.

Clinical trials have played an essential role in the discovery of critical treatments and vaccines in modern medicine, and yet the question of how they could be done better in order to improve public health outcomes has not had the attention it deserves — until now.

Statement |

17 November 2022

MSF publishes first Clinical Trial Transparency Policy

MSF publicly announced its first Clinical Trial Transparency Policy (CTTP). The CTTP outlines MSF’s commitment to the open sharing of information and costs on clinical trials.

Tags Research and development World Health Organization

Events |

17 November 2022

How can disclosing clinical trial costs increase access to medical products?

On November 17th, 2022, MSF Access Campaign held a second roundtable on the need for transparency around clinical trials costs - why and how it could be done.

Tags Research and development

Video |

14 November 2022

Diabetes challenges

On 14th November 2022, World Diabetes Day, the MSF Access Campaign called for everyone in need to have access to the full treatment ‘bundle’ (insulin, injection devices and monitoring tools) they need to stay alive.

Tags Diabetes Diabetes Insulin

Technical brief |

11 November 2022

MSF Clinical Trial Transparency Policy

This policy is a commitment to publishing research protocols, registering clinical trials on appropriate registries, and subsequently publishing clinical trial data in open access formats, in line with the WHO’s joint statement on ...

Tags TransparencyResearch and development

Issue brief |

08 November 2022

DR-TB Drugs Under the Microscope, 8th Edition

TB was the leading cause of death from a single infectious agent until the COVID pandemic. The number of people newly diagnosed with TB in 2020 fell by 18% from the previous year due to disruptions to health systems and services caused ...

Tags Tuberculosis tuberculosis DRTB Drugs Under the Microscope

Prachi, an MSF nurse, performs a pre-infusion procedure for Chetan, who lives with DR-TB.

Press release |

08 November 2022

New MSF report warns that major opportunity to increase access to newer, safer DR-TB drugs is at risk

A MSF report released today finds that two newer TB drugs – bedaquiline and delamanid – going off patent in 2023 presents a critical opportunity to increase access to shorter, safer and better treatment for people with drug-resistant ...

Tags Tuberculosis tuberculosis TB Alliance

Video |

03 November 2022

MSF commitment to supporting the objectives of the ‘1/4/6 by 24’ campaign

MSF commits to the following actions in support of the ‘1/4/6 by 24’ campaign.

Tags Tuberculosis tuberculosis

Technical brief |

02 November 2022

Damaging provisions for access to medicines in the UK-India FTA negotiation text

The UK has tabled harmful provisions that threaten to tighten the screws on producing, supplying and exporting affordable generic medicines from India

Tags Intellectual property and trade TRIPS WTO

XDR-TB patient Hanif, during his weekly consultation with Dr. Joan, at MSF’s clinic in Mumbai.

Press release |

02 November 2022

MSF responds to UK's disastrous proposal on intellectual property in UK-India Free Trade Agreement

UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely

Tags Intellectual property and trade TRIPS WTO United KingdomIndia

MSF Counsellor, counselling parents of a six-year-old girl with drug-resistant TB at MSF independent Clinic, Mumbai- India

Press release |

27 October 2022

MSF responds to WHO Global TB Report 2022, calls for scale up of shorter and safer DR-TB treatments to help save more lives

MSF reiterates that the price of a full DR-TB treatment course should be no more than US$500 per person.

Tags Tuberculosis tuberculosis World Health Organization

Topic overview

Transparency Matters: Clinical Trial Costs

Clinical trials are widely accepted as the most expensive part of the medical innovation cycle and therefore likely make up a significant portion of total R&D costs. But there is no transparency around the actual costs of clinical ...

Tags Research and development

Haiti CTC Turgeau – MSF Health Promoter Jose verifies and keeps track on the health conditions of ill patients.

Press release |

19 October 2022

MSF responds to change in global cholera vaccine strategy amid unprecedented number of outbreaks

Due to the high number of countries currently experiencing cholera outbreaks and a shortage of oral cholera vaccine, the International Coordinating Group (ICG) announced today that it will temporarily suspend the standard two-dose ...

Tags Tropical & neglected diseases cholera World Health Organization

Technical brief |

17 October 2022

Roundtable: How Can Disclosing Clinical Trial Costs Increase Access to Medical Products?

Clinical trial cost transparency can inform evidence-based policy making and enable governments and treatment providers to regulate and negotiate prices more effectively.

Tags Research and development World Health Assembly

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Toxicon: X: Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues

MSF responds to groundbreaking updated WHO guidelines for drug-resistant tuberculosis

The Lancet Gastroenterology & Hepatology: An open letter to Gavi: hepatitis B birth dose vaccine can't wait

Civil Society Open Letter to the Council of the European Union Concerning Transferable Exclusivity Vouchers for Antimicrobials

Working for access to long-acting cabotegravir for HIV prevention

Pharmaceutical corporation ViiV must make ground-breaking HIV prevention injection affordable and available

How much do clinical trials cost? The answer is overdue.

MSF publishes first Clinical Trial Transparency Policy

How can disclosing clinical trial costs increase access to medical products?

Diabetes challenges

MSF Clinical Trial Transparency Policy

DR-TB Drugs Under the Microscope, 8th Edition

New MSF report warns that major opportunity to increase access to newer, safer DR-TB drugs is at risk

MSF commitment to supporting the objectives of the ‘1/4/6 by 24’ campaign

Damaging provisions for access to medicines in the UK-India FTA negotiation text

MSF responds to UK's disastrous proposal on intellectual property in UK-India Free Trade Agreement

MSF responds to WHO Global TB Report 2022, calls for scale up of shorter and safer DR-TB treatments to help save more lives

Transparency Matters: Clinical Trial Costs

MSF responds to change in global cholera vaccine strategy amid unprecedented number of outbreaks

Roundtable: How Can Disclosing Clinical Trial Costs Increase Access to Medical Products?